Examining the tolerability of the non-sedating antihistamine desloratadine: A prescription-event monitoring study in England

Drug Safety

Volumn 32, Issue 2, 2009, Pages 169-179

  Layton, Deborah ^a,b   Wilton, Lynda ^a,b   Shakir, Saad A W ^a,b  

^a DRUG SAFETY RESEARCH UNIT   (United Kingdom)

^b UNIVERSITY OF PORTSMOUTH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CETIRIZINE; DESLORATADINE; FEXOFENADINE; LORATADINE;

ADULT; AGED; ALLERGIC RHINITIS; ALLERGY; ARTICLE; ASTHMA; BRADYCARDIA; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; CONVULSION; COUGHING; DEMOGRAPHY; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EYE DISEASE; FEMALE; FLUENCY DISORDER; GENERAL PRACTITIONER; HEADACHE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART PALPITATION; HUMAN; LASSITUDE; MAJOR CLINICAL STUDY; MALAISE; MALE; MIGRAINE; MISSED ABORTION; MONITORING; NECK PAIN; PERIPHERAL NEUROPATHY; PHOTOSENSITIVITY; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; RECOMMENDED DRUG DOSE; SCHOOL CHILD; SEDATION; SIDE EFFECT; SORE EYE; SPONTANEOUS ABORTION; SYNCOPE; THERAPEUTIC ABORTION; THORAX PAIN; UNITED KINGDOM; URTICARIA; WHEEZING;

ADULT; COHORT STUDIES; DRUG PRESCRIPTIONS; DRUG UTILIZATION; ENGLAND; FEMALE; HEADACHE; HISTAMINE H1 ANTAGONISTS; HUMANS; LORATADINE; MALE; PHYSICIANS, FAMILY; PREGNANCY; URINARY TRACT INFECTIONS;

EID: 60749103321     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200932020-00009     Document Type: Article

References (53)

1. Schering-Plough Europe. Summary of product characteristics: Neoclarityn (desloratadine) 5mg tablets. Belgium: SP Europe, 2001 Jan
2. Schering-Plough Europe. Summary of product characteristics: Neoclarityn (desloratadine) 5mg tablets. Belgium: SP Europe, 2005 Jan
3. Meltzer EO. Comparative safety of H1 antihistamines. Ann Allergy 1991 Dec; 67 (6): 625-33
4. Yap YG, Camm J. Risk of torsades de pointes with non-cardiac drugs: doctors need to be aware that many drugs can cause QT prolongation. BMJ 2000 Apr 29; 320 (7243): 1158-9
5. Clark S. Dangers of non-sedating antihistamines. [letter]. Lancet 1997 May 3; 349 (9061): 1268
6. Shakir S. Prescription-event monitoring. In: Strom BL, editor. Pharmacoepidemiology. 4th ed. Chichester: John Wiley & Sons Ltd, 2005: 203-16
7. CIOMS/WHO. International guidelines for biomedical research involving human subjects. Geneva: CIOMS, 2002
8. Royal College of Physicians of London. Guidelines on the practice of ethical committees in medical research involving human subjects. London: RCP, 1996
9. General Medical Council. Frequently asked questions supplement to: confidentiality: protecting and providing information. London: General Medical Council, 2004: 9
10. Spector SL. Overview of comorbid associations of allergic rhinitis. J Allergy Clin Immunol 1997 Feb; 99 (2): S773-80
11. Bachert C, Virchow Jr CJ, Plenker A. Desloratadine in the treatment of seasonal allergic rhinitis: results of a large observational study. Clin Drug Invest 2002; 22 Suppl. 2: 43-52
12. Broide DH. Molecular and cellular mechanisms of allergic disease. J Allergy Clin Immunol 2001 Aug; 108 (2 Suppl.): S65-71
13. Baena-Cagnani CE. Desloratadine activity in concurrent seasonal allergic rhinitis and asthma. Allergy 2001; 56 Suppl. 65: 21-7
14. Shakir S. Causality and correlation in pharmacovigilance. In: Talbot J, Waller P, editors. Stephens' detection of new adverse drug reactions. 5th ed. Chichester: John Wiley & Sons Ltd, 2004: 329-43
15. Shakir SA. PEM in the UK. In: Mann RD, Andrews E, editors. Pharmacovigilance. 1st ed. Chichester: John Wiley & Sons Ltd, 2002: 333-44
16. Heeley E, Riley J, Layton D, et al. Prescription-event monitoring and reporting of adverse drug reactions. Lancet 2001 Dec 1; 358 (9296): 1872-3
17. Martin RM, Kapoor KV, Wilton LV, et al. Underreporting of suspected adverse drug reactions to newly marketed ("black triangle") drugs in general practice: observational study. BMJ 1998 Jul 11; 317 (7151): 119-20
18. De Ponti F, Poluzzi E, Montanaro N. QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience. Eur J Clin Pharmacol 2000 Apr; 56 (1): 1-18
19. Ring J, Hein R, Gauger A, et al. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Int J Dermatol 2001 Jan; 40 (1): 72-6
20. Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J 2004 Nov; 24 (5): 758-64
21. Kozel MM, Sabroe RA. Chronic urticaria: aetiology, management and current and future treatment options. Drugs 2004; 64 (22): 2515-36
22. DuBuske L. Pharmacology of desloratadine: special characteristics. Clin Drug Invest 2002; 22 Suppl. 2: 1-11
23. Henz BM. The pharmacologic profile of desloratadine: a review. Allergy 2001; 56 Suppl. 65: 7-13
24. Satish U, Streufert S, Dewan M, et al. Improvements in simulated real-world relevant performance for patients with seasonal allergic rhinitis: impact of desloratadine. Allergy 2004 Apr; 59 (4): 415-20
25. Verster J, De Weert A, Bijtjes S, et al. Driving ability after acute and sub-chronic administration of levocetirizine and diphenhydramine: a randomized, double-blind, placebo-controlled trial. Psychopharmacology 2003; 169: 84-90
26. Simons FE. Advances in H1-antihistamines. N Engl J Med 2004 Nov 18; 351 (21): 2203-17
27. Spangler DL, Brunton S. Efficacy and central nervous system impairment of newer-generation prescription antihistamines in seasonal allergic rhinitis. South Med J 2006 Jun; 99 (6): 593-9
28. Schering Corporation. Clarinex (desloratadine product information package insert) [online]. Available from URL: http://www.spfiles.com/piclarinex.pdf [Accessed 2007 Nov 15]
29. Geha RS, Meltzer EO. Desloratadine: a new, nonsedating, oral antihistamine. J Allergy Clin Immunol 2001 Apr; 107 (4): 751-62
30. Layton D, Wilton L, Boshier A, et al. Comparison of the risk of drowsiness and sedation between levocetirizine and desloratadine: a prescription-event monitoring study in England. Drug Saf 2006; 29 (10): 897-909
31. Rankin AC. Non-sedating antihistamines and cardiac arrhythmia. Lancet 1997 Oct 18; 350 (9085): 1115-6
32. Yap YG, Camm AJ. Arrhythmogenic mechanisms of non-sedating antihistamines. Clin Exp Allergy 1999 Jul; 29 Suppl. 3: 174-81
33. Davies AJ, Harindra V, McEwan A, et al. Cardiotoxic effect with convulsions in terfenadine overdose. BMJ 1989 Feb 4; 298 (6669): 325
34. Honig PK, Woosley RL, Zamani K, et al. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 1992 Sep; 52 (3): 231-8
35. Mathews DR, McNutt B, Okerholm R, et al. Torsades de pointes occurring in association with terfenadine use. JAMA 1991 Nov 6; 266 (17): 2375-6
36. Monahan BP, Ferguson CL, Killeavy ES, et al. Torsades de pointes occurring in association with terfenadine use. JAMA 1990 Dec 5; 264 (21): 2788-90
37. Woosley RL. Cardiac actions of antihistamines. Annu Rev Pharmacol Toxicol 1996; 36: 233-52
38. Zimmermann M, Duruz H, Guinand O, et al. Torsades de pointes after treatment with terfenadine and ketoconazole. Eur Heart J 1992 Jul; 13 (7): 1002-3
39. Simons FE, Kesselman MS, Giddins NG, et al. Astemizole-induced torsades de pointes [letter]. Lancet 1988 Sep 10; 2 (8611): 624
40. Snook J, Boothman-Burrell D, Watkins J, et al. Torsades de pointes ventricular tachycardia associated with astemizole overdose. Br J Clin Pract 1988 Jun; 42 (6): 257-9
41. De Bruin ML, van Puijenbroek EP, Egberts AC, et al. Non-sedating antihistamine drugs and cardiac arrhythmias: biased risk estimates from spontaneous reporting systems? Br J Clin Pharmacol 2002 Apr; 53 (4): 370-4
42. Kreutner W, Hey JA, Chiu P, et al. Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist. 2nd communication: lack of central nervous system and cardiovascular effects. Arzneimittelforschung 2000 May; 50 (5): 441-8
43. Gilbert C, Mazzotta P, Loebstein R, et al. Fetal safety of drugs used in the treatment of allergic rhinitis: a critical review. Drug Saf 2005; 28 (8): 707-19
44. Kallen B. Use of antihistamine drugs in early pregnancy and delivery outcome. J Matern Fetal Neonatal Med 2002 Mar; 11 (3): 146-52
45. Centers for Disease Control and Prevention (CDC). Evaluation of an association between loratadine and hypospadias: United States, 1997-2001. MMWR Morb Mortal Wkly Rep 2004 Mar 19; 53 (10): 219-21
46. Loratadine, desloratadine and pregnancy: don't use, risk of hypospadias [letter]. Prescrire Int 2003 Oct; 12 (67): 183
47. Bachert C, van Cauwenberge P. The WHO ARIA (allergic rhinitis and its impact on asthma) initiative. Chem Immunol Allergy 2003; 82: 119-26
48. Bauchau V, Durham SR. Epidemiological characterization of the intermittent and persistent types of allergic rhinitis. Allergy 2005 Mar; 60 (3): 350-3
49. Khanna P, Shah A. Categorization of patients with allergic rhinitis: a comparative profile of "sneezers and runners" and "blockers" . Ann Allergy Asthma Immunol 2005 Jan; 94 (1): 60-4
50. Crystal-Peters J, Neslusan C, Crown WH, et al. Treating allergic rhinitis in patients with comorbid asthma: the risk of asthma-related hospitalizations and emergency department visits. J Allergy Clin Immunol 2002 Jan; 109 (1): 57-62
51. Bousquet J, Boushey HA, Busse WW, et al. Characteristics of patients with seasonal allergic rhinitis and concomitant asthma. Clin Exp Allergy 2004 Jun; 34 (6): 897-903
52. Meltzer EO, Prenner BM, Nayak A, et al. Efficacy and tolerability of once-daily 5 mg desloratadine, an H1 receptor antagonist, in patients with seasonal allergic rhinitis: assessment during the Spring and Fall allergy seasons. Clin Drug Invest 2001; 21 (1): 25-32
53. Laforest L, Bousquet J, Pietri G, et al. Quality of life during pollen season in patients with seasonal allergic rhinitis with or without asthma. Int Arch Allergy Immunol 2005 Mar; 136 (3): 281-6